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A novel mutation in the TG gene (G2322S)
causing congenital hypothyroidism in a
Sudanese family: a case report
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Abstract
Background: Congenital hypothyroidism (CH) has an incidence of approximately 1:3000, but only 15% have
mutations in the thyroid hormone synthesis pathways. Genetic analysis allows for the precise diagnosis.
Case presentation: A 3-week old girl presented with a large goiter, serum TSH > 100 mIU/L (reference range: 0.7–5.9
mIU/L); free T4 < 3.2 pmol/L (reference range: 8.7–16 pmol/L); thyroglobulin (TG) 101 μg/L. Thyroid Tc-99 m scan
showed increased radiotracer uptake. One brother had CH and both affected siblings have been clinically and
biochemically euthyroid on levothyroxine replacement. Another sibling had normal thyroid function. Both Sudanese
parents reported non-consanguinity. Peripheral blood DNA from the proposita was subjected to whole exome
sequencing (WES). WES identified a novel homozygous missense mutation of the TG gene: c.7021G > A, p.Gly2322Ser,
which was subsequently confirmed by Sanger sequencing and present in one allele of both parents. DNA samples
from 354 alleles in four Sudanese ethnic groups (Nilotes, Darfurians, Nuba, and Halfawien) failed to demonstrate the
presence of the mutant allele. Haplotyping showed a 1.71 centiMorgans stretch of homozygosity in the TG locus
suggesting that this mutation occurred identical by descent and the possibility of common ancestry of the parents.
The mutation is located in the cholinesterase-like (ChEL) domain of TG.
Conclusions: A novel rare missense mutation in the TG gene was identified. The ChEL domain is critical for protein
folding and patients with CH due to misfolded TG may present without low serum TG despite the TG gene mutations.
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Background
Congenital hypothyroidism (CH) has a worldwide inci-
dence of 1:1500 to 1:4000 depending on the TSH cut-off
value used in neonatal screening (NS) [1, 2]. Mutations
in multiple genes have been shown to cause CH and are
grouped into several categories depending on the pres-
ence or absence of goiter, level of serum thyroglobulin
(TG), and other clinical characteristics [3]. TG is synthe-
sized by the thyroid gland and its primary functions
include iodide storage and thyroid hormonogenesis.
Thyroxine (T4), the predominant form of thyroid
hormone (TH), is produced by iodination of select
tyrosine residues and coupling pairs of doubly iodinated
tyrosines within TG molecules. TG is essential for TH
synthesis and homozygous or compound heterozygous
mutations of the TG gene can result in permanent CH. To
date, 117 TG gene mutations have been reported [4–6].
Most cases with CH due to TG gene mutations show de-
creased serum TG levels.
We report an unusual case identified in Australia
involving a Sudanese family with familial CH presenting
with goiter and without low serum TG level.
Case presentation
Clinical report
The CARE guidelines were followed in this case. A 3-week
old girl born to Sudanese parents in Brisbane, Australia,
presented with a large goiter causing upper airway
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obstruction and producing stridor. Her thyroid stimulating
hormone (TSH) on NS was 14 mIU/L (cut-off range for
notification: > 13 mIU/L). The result was communicated to
the relevant clinicians but, unfortunately, appropriate
follow-up had not occurred. At 3 weeks of age when she
presented with goiter, serum analysis showed a TSH > 100
mIU/L (reference range: 0.7–5.9 mIU/L) with low free T4
of < 3.2 pmol/L (reference range: 8.7–16 pmol/L) and high
TG of 101 μg/L (reference range for all age: 1.6–59.9 μg/L).
The urinary iodine concentration was 0.63 μmol/L, suggest-
ing that she had mild iodine deficiency. Thyroid ultrasound
and MRI (Fig. 1a) showed both lobes of the thyroid gland
to be significantly enlarged. Nuclear scan following injec-
tion of 42 MBq Tc-99 m pertechnetate showed a large
goiter with homogeneous markedly increased radiotracer
uptake (Fig. 1b). Levothyroxine replacement was started
based on the diagnosis of CH as standard of care.
Her brother was also found to be hypothyroid based
on NS, with an elevated TSH of 60 mIU/L. He had been
on levothyroxine replacement since that time, with no
concerns regarding growth or development. His thyroid
ultrasound and nuclear scan at 2 years of age showed a
eutopic thyroid gland with increased nuclear tracer up-
take of 5.2% (normal range 1–4%) following withdrawal
of levothyroxine replacement for 5 days. Both siblings
had TSH and TH concentrations in the reference ranges
while under levothyroxine replacement and with dose ad-
justment and they have been clinically euthyroid (Fig. 2).
The proposita’s TG decreased to 2.2 μg/L and the affected
brother had low TG of 0.3 μg/L. Other members of the
family had no symptoms and their thyroid tests were nor-
mal (Fig. 2). Subsequent perchlorate discharge studies
were performed on the affected brother following with-
drawal of levothyroxine replacement for 3 weeks [TSH
180 mIU/L (reference range: 0.7–4.0 mIU/L), FT4 4.
4 pmol/L (reference range: 7.5–17 pmol/L), TG 9.6 μg/L]
and on both parents. The results demonstrated increased
uptake of radiotracer in the brother and normal tracer
uptake in the parents with no washout of I-123 following
perchlorate administration (Fig. 3). This suggests preser-
vation of the organification process [7]. Both maternal and
paternal families are non-consanguineous and of Sudanese
origin (maternal grandfather; Gogrial and maternal grand-
mother and paternal grandparents; Aweil East, of South
Sudan, respectively). There was no history of thyroid
disorders in either family.
Molecular genetics
Genomic DNA was extracted from peripheral blood
leukocytes as previously described [8]. The proposita’s
DNA was submitted to whole exome sequencing. A
panel of 50 genes related to thyroid development, func-
tion, serum and cell TH transport and hormone synthe-
sis was evaluated (Additional file 1: Table S1). This led
to the identification of a novel homozygous missense
mutation in exon 40 of the TG gene: c.7021G >A, p.
Gly2322Ser (numbering excludes 19 amino acid signal pep-
tide). All exonic variants in the TG gene identified in the
proposita are summarized in Additional file 2: Table S2.
Sanger sequencing confirmed that the affected brother (III-
2) was homozygous for the same mutation while the par-
ents (II-2 and II-3) and maternal grandmother (I-4) were
heterozygous for this mutation, indicating that they were
unaffected carriers (Fig. 4a). The other brother (III-1) and
the maternal grandfather (I-3) had the wild-type genotype
and normal thyroid function tests (Fig. 2 and 4a). This vari-
ant was not present in the Genome Aggregation Database
(gnomAD) used for analysis. Since the database did not
likely include a large number of Sudanese individuals, 354
alleles from 4 Sudanese ethnic groups (Nilotes, Darfurians,
Nuba, and Halfawien) [9] were also used for analysis. The
TG mutation identified in our family was not present in
the 177 Sudanese individuals, suggesting that the variant is
rare in the Sudanese as well. Single nucleotide polymor-
phisms (SNPs) markers with high allele frequencies in the
TG locus and markers in the flanking genes were
Fig. 1 Radiological investigations of the proposita at three weeks of age. a Magnetic Resonance Imaging of the neck showing significant enlargement
and extension of the thyroid gland. The thyroid encircles the laryngeal and tracheal lucency, extending posteriorly almost to the midline. Inferiorly, it
extends posterior to the clavicle with no retrosternal extension. b Tc-99 m pertechnetate thyroid scan demonstrating significantly increased
radiotracer uptake
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genotyped to reconstruct the haplotype for the region
(8q24.22) (Fig. 5). The haplotype associated with CH
present in both parents was identical for a stretch of ~ 1.71
centiMorgans (cM). The G2322S TG mutation affects a
highly conserved amino acid in various species (Fig. 4b)
and functional in silico prediction algorithms suggest that
this mutation is deleterious (SIFT; 0.001, deleterious and
PolyPhen2; 1.0, probably damaging).
Discussion and Conclusions
A novel homozygous TG gene mutation was identified
in two children with CH and goiter. The unrelated par-
ents are heterozygous for this “rare” mutation and, sur-
prisingly, report non-consanguinity. Haplotype analysis
of the SNP makers revealed that the haplotype contain-
ing the mutated allele was homozygous over the entire
TG locus, spanning 1.71 cM (Fig. 5). This is consistent
with the autosomal recessive pattern of inheritance [10].
These results suggest that the mutation occurred identi-
cal by descent [11] and that the parents have distant
common ancestry [12]. This is likely because Sudan is
known for high prevalence of consanguineous marriage
[13] and it has been reported that marriage between 1st
cousins accounted for more than 40% marriages [14].
DNA obtained from a Sudanese cohort [9] was analyzed
by Sanger sequencing to confirm the frequency of the
mutation in the population. However, none of 177 indi-
viduals had the mutated allele, indicating the minor
allele frequency (MAF) for this variant to be less than 0.
3% in the Sudanese population.
The TG protein is composed of three consecutive cyst-
eine (Cys) repeat domains (domains I, II, and III) form-
ing many disulfide bonds. These Cys repeat-domains are
followed by the cholinesterase-like (ChEL) domain [4].
Although the TG protein contains 120 Cys, the ChEL
domain contains only six Cys. While the mutation in the
present case does not directly substitute a Cys residue, it
is located in the ChEL domain and is similar to six
pathogenic missense mutations previously reported in
the domain. Two mutations in the domain (p.A2215D
and p.R2223H) occur before the first disulfide bond of
ChEL, whereas the remaining four mutations (p.
G2300D, p.R2317Q, p.G2355 V, and p.G2356R) fall be-
tween the first and second disulfide bonds. The G2322S
variant in the present case also resides between the first
and second disulfide bonds of the ChEL domain (Fig. 6).
We used JPred 4 server for prediction of the secondary
structure of the TG [15]. Although the first loop created
by the first and second disulfide bonds in the ChEL do-
main are located away from the α7/8 and α10 helices,
associated with TG dimerization, or any other α helix
motif, the first loop is considered to be important for
Fig. 2 Pedigree of the family and results of thyroid function tests. Each generation corresponds to a roman number. Arabic numbers above each
symbol identify the subjects. Laboratory data are aligned below each symbol. Abnormal values are in bold type. Abbreviations: L-T4; levothyroxine, TT4;
total thyroxine, TT3; total triiodothyronine, FT4; free thyroxine, TSH; thyroid-stimulating hormone, TBG; thyroxine binding globulin, TG; thyroglobulin,
TPO Ab; anti-TPO antibody, TG Ab; anti-thyroglobulin antibody. The International System of Units: TT4; μg/dL = 12.87 nmol/L, TT3; ng/dL = 0.0154 nmol/
L, FT4; ng/dL = 12.87 pmol/L, TBG; μg/mL = 0.0185 μmol/L
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ChEL folding [4]. Interestingly, all pathogenic missense
mutations in the ChEL domain are not located in the α
helix, however they have been shown to result in CH.
Animal studies confirmed that a misfolded TG resulted
from similar variants in the ChEL domain. Introduction
of p.L2263P in a mouse produced congenital goiter dem-
onstrating that the mutation permitted full-length syn-
thesis of TG but impaired folding necessary for TG
homodimerization and transport from the endoplasmic
reticulum (ER) [16, 17]. Another rodent, the rdw rat,
harboring the TG p.G2300R mutation exhibited ab-
normal folding of TG resulting in an extended α helix
within the ChEL domain and retention of TG within
the ER lumen [18]. The p.G2322S mutation in the
present case is located near these mutations, suggest-
ing that TG folding, transport and secretion might be
similarly impaired.
Most cases with CH due to the TG gene mutations
show decreased serum TG levels before TH replacement
and it is a key factor for the diagnosis of TG defects [6, 19].
Interestingly, the present case had a TG of 101 μg/L at
diagnosis. Reference range of serum TG for infants have
not been established. Depending on the platform of ana-
lysis, the upper limit of normal for infants between 15 and
180 days was from 43.37 to 147.28 μg/L [20]. Due to lack
of a specific TG reference range for infants using our
method (IMMULITE 2000 ®; Siemens, Germany), the TG
value of the present case may be high normal, but defin-
itely above values reported in individuals with the TG gene
mutations. Moreover, her TG decreased as TSH fell. The
affected brother (III-2) had the same mutation in the TG
gene, although his TG before levothyroxine replacement
Fig. 4 a Direct sequencing for normal (Wild type/Wild type), heterozygote (Mutant/Wild type) and homozygote (Mutant/Mutant) covering the
region of the mutation in exon 40 of the TG gene (c.7021G > A, pGly2322Ser). b Alignment of the TG amino acid sequence encoded by exons
40 and 41 containing the mutant Gly2322 in various species including mammals, amphibian and fish. Amino acid differences are in bold type.
Abbreviations: WT; Wild type, Mut; Mutant
Fig. 3 I-123 and perchlorate discharge thyroid scans for the proposita’s
brother (a & b), father (c & d), and mother (e & f). All subjects
demonstrated no discharge following perchlorate administration
consistent with preservation of the organification process
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therapy was unknown. Among 61 cases in which serum
TG values without TH replacement were reported, only
three cases, beside the present case, showed increased TG
(Table 1) [21–23]. The TG mutations p.C1977S and p.
A2215D have been reported in multiple cases, and levels of
TG in the affected, not included in the list, were normal or
low. As with the p.G2322S or p.A2215D in the ChEL do-
main, the p.C1977S located in the Cys repeat domain III
was also associated with misfolding [21, 24]. In general, un-
folded protein is blocked from being transported within a
cell and then refolded or degraded by chaperone proteins
through an intracellular signaling pathway called unfolded
protein response (UPR) [24]. Interestingly, absence of the
chaperone protein activation was observed in the p.
C1977S case with hyperthyroglobulinemia [24]. Thus, in-
complete UPR may be associated with secretion of some
mutated TG without retention in the ER resulting in
higher serum TG. The initial serum TG level of the present
case was 101 μg/L. In contrast, CH due to TPO deficiency,
in 63 published cases in whom the TG gene was normal
had on the average serum TG of more than 1000 μg/L be-
fore TH replacement [25–27]. Therefore the TG mutation
in the present case resulted in a lesser serum TG level than
that observed in CH due to TPO mutations but higher
than that of patients with TG gene mutations in the major-
ity of whom serum TG is undetectable or less than 5 μg/L
[19]. The higher level of serum TG in the present case sug-
gests reduced secretion or rapid degradation of a misfolded
molecule. As mentioned above, several other cases of TG
gene mutations manifesting serum TG levels above 5 μg/L
have been reported [21–23].
The affected sibling of the proposita homozygous for
the TG mutation had an elevated TSH on NS whereas
the proposita (also homozygous for the same mutation)
did not. “Delayed TSH rise” has been reported in pre-term
and low-birth weight newborns and also some cases with
thyroid dyshormonogenesis [28–30]. Incomplete develop-
ment of hypothalamic-pituitary axis or acute iodine over-
load is possible cause of the phenomenon. However, the
precise pathophysiological mechanisms are still unclear.
Fig. 5 Haplotypes present in the family members using single nucleotide polymorphic markers. Black filled, semi-round or semi-square and open symbols
indicate affected individuals, unaffected carriers and wild type, respectively. The inherited portion of the disease associated haplotype is indicated in
blackened bar. a) Marker location on the human genome reference sequence (NCBI Build 38). b) Marker location on the international HapMap project
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Fig. 6 Schematic representation of ChEL domain in the TG gene. Amino acid numbering is indicated above TG structure. α helix motifs are
indicated in gray boxes with diagonal lines. Cystein residues are indicated in black lines. Pathogenic missense mutations are indicated in gray
lines. *Mutation in the present case
















33 c.5985 T > A p.C1977S Repeat domain III adult
F
+ 1.7 [0.1–4.0] N/A 9.8 [8–28] 181 [15–50] negative [21]
33 c.5985 T > A p.C1977S Repeat domain III adult
F
+ 1.2 [0.1–4.0] N/A 9.1 [8–28] 117 [15–50] negative [21]
38 c.6701C > A p.A2215D ChEL 34 yrs.
M
+ 4 [0.5–4.5] 6 [4–12] N/A 29.2 [1.5–15] N/A [22, 23]
40 c.7021G > A p.G2322S ChEL 3 wks
F
+ > 100 [0.7–5.9] < 3.2 [8.7–16] N/A 101 [N/A] negative III-3, this
report
All patients were without TH replacement at the thyroid function tests
Abbreviations: TG thyroglobulin, TSH thyroid-stimulating hormone, TT4 total thyroxine, FT4 free thyroxine, N/A not available, L-T4; levothyroxine, ChEL
cholinesterase-like, F Female, M Male, yrs years, wks weeks
The International System of Units: TT4; μg/dL = 12.87 nmol/L
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The delayed TSH rise in the proposita may be due to an
unknown genetic cause or an environmental factor such
as iodine exposure.
In conclusion, a novel homozygous mutation in the TG
gene was identified. The mutation was not found in four
Sudanese groups of different ethnic origin (n = 177). The
mutation is located in the ChEL domain of the TG which
is essential for protein folding. Patients with CH due to
misfolded TG may present without low serum TG.
Additional files
Additional file 1: Table S1. Genes related to thyroid disorder. 50 genes
related to thyroid development, function, serum and cell TH transport
and hormone synthesis. (XLSX 30 kb)
Additional file 2: Table S2. Exonic variants in the TG gene identified in
the proposita by whole exome sequencing. All exonic variants in the TG
gene identified in the proposita. (XLSX 41 kb)
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